MEI Pharma Inc MEIP

NAS: MEIP | ISIN: US55279B2025   30/04/2025
2,040 USD (+2,00%)
(+2,00%)   30/04/2025

22 september 2021 · MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference · Persbericht

3 september 2021 · MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 september 2021 · MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights · Persbericht

2 september 2021 · MEI Pharma to Present at Two Healthcare Conferences · Persbericht

26 augustus 2021 · MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021 · Persbericht

17 augustus 2021 · MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma · Persbericht

5 augustus 2021 · MEI Pharma Announces Planned Chief Financial Officer Transition · Persbericht

2 augustus 2021 · MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) · Persbericht

7 juli 2021 · MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer · Persbericht

1 juli 2021 · MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) · Persbericht

9 juni 2021 · MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program · Persbericht

7 juni 2021 · MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib · Persbericht

4 juni 2021 · MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting · Persbericht

19 mei 2021 · MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021 · Persbericht

12 mei 2021 · MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress · Persbericht

6 mei 2021 · MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights · Persbericht

30 april 2021 · MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer · Persbericht

10 april 2021 · MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers · Persbericht

5 april 2021 · MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference · Persbericht

10 maart 2021 · MEI Pharma to Present Study at the American Association for Cancer Research (AACR) Annual Meeting 2021 Demonstrating that Voruciclib Inhibits KRAS Mutant Cancers in Pre-Clinical Models · Persbericht

Mijn selecties